NCT00191308

Molecular Profiling in Lung Cancer Patients

Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment.

Conditions

• Non-Small Cell Lung Cancer
• Carcinoma

Interventions

Type	Name	Description
DRUG	pemetrexed	500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
DRUG	cisplatin	75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
PROCEDURE	Radical Non-Small Cell Lung Cancer (NSCLC) surgery	All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-07-01
• Completion: 2010-12-01
• First posted: 2005-09-19
• Last updated: 2011-10-21
• Results posted: 2010-04-20

Locations

3 sites across 1 country: Poland